Preventive immunization of aged and juvenile non-human primates to beta-amyloid

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Kofler, Julia ^a   Lopresti, Brian ^a   Janssen, Chris ^b   Trichel, Anita M ^b   Masliah, Eliezer ^c   Finn, Olivera J ^a   Salter, Russell D ^a   Murdoch, Geoffrey H ^a   Mathis, Chester A ^a   Wiley, Clayton A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active immunization; Alzheimer's disease; Beta amyloid; Classical and alternative activation; Immunosenescence; Microglia; Neuroinflammation; Oligomers; Preventive immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CARBON 11; DIMER; IMMUNOGLOBULIN G; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PHOSPHORYL LIPID A; TAU PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CELL ACTIVATION; CELL DENSITY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84860369530     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-84     Document Type: Article

References (87)

1. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98:8850-8855. 10.1073/pnas.151261398, 37524, 11438712.
2. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177. 10.1038/22124, 10408445.
3. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48:567-579. 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W, 11026440.
4. Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav Neurosci 2003, 117:478-484.
5. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5:452-457.
6. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982. 10.1038/35050110, 11140685.
7. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22:6331-6335.
8. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006, 26:4717-4728. 10.1523/JNEUROSCI.0381-06.2006, 16672644.
9. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985. 10.1038/35050116, 11140686.
10. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562. 10.1212/01.WNL.0000159740.16984.3C, 15883316.
11. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554. 10.1016/S0896-6273(03)00294-0, 12765607.
12. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009, 6:144-151. 10.2174/156720509787602852, 2825665, 19355849.
13. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol 2010, 6:108-119. 10.1038/nrneurol.2009.219, 2864089, 20140000.
14. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54. 10.1212/01.WNL.0000073623.84147.A8, 12847155.
15. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009, 30:1026-1036. 10.1016/j.neurobiolaging.2009.04.002, 2737680, 19376612.
16. Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009, 8:144-159. 10.2174/187152709787847324, 2812706, 19355934.
17. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310. 10.1093/brain/awn261, 18953056.
18. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6:e16032. 10.1371/journal.pone.0016032, 3020224, 21264269.
19. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011, 32:S20-S36.
20. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349. 10.1001/archneur.64.3.noc60123, 17210801.
21. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393. 10.1001/jama.2009.1064, 19622817.
22. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010, 7:34. 10.1186/1742-2094-7-34, 2892443, 20540736.
23. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010, 68:903-912. 10.1016/j.biopsych.2010.08.025, 3011944, 21035623.
24. Venneti S, Bonneh-Barkay D, Lopresti BJ, Bissel SJ, Wang G, Mathis CA, Piatak M, Lifson JD, Nyaundi JO, Murphey-Corb M, Wiley CA. Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am J Pathol 2008, 172:1603-1616. 10.2353/ajpath.2008.070967, 2408420, 18467697.
25. Tai C, Chatziioannou A, Siegel S, Young J, Newport D, Goble RN, Nutt RE, Cherry SR. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol 2001, 46:1845-1862. 10.1088/0031-9155/46/7/308, 11474929.
26. Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, Sacktor NC, McArthur JC, Pomper MG. Imaging glial cell activation with [11 C]-R-PK11195 in patients with AIDS. J Neurovirol 2005, 11:346-355. 10.1080/13550280500187351, 16162478.
27. Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009, 66:60-67. 10.1001/archneurol.2008.511, 2666881, 19139300.
28. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005, 25:1528-1547. 10.1038/sj.jcbfm.9600146, 15944649.
29. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005, 46:1959-1972.
30. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, Tian W, Sadzikava N, Ross TM, Head E, Cribbs DH, Agadjanyan MG. Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol 2003, 33:3232-3241. 10.1002/eji.200324000, 1524857, 14635031.
31. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20:127-132. 10.1097/00002093-200607000-00001, 16917180.
32. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004, 165:283-297. 10.1016/S0002-9440(10)63296-8, 1618542, 15215183.
33. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 2010, 277:3051-3067. 10.1111/j.1742-4658.2010.07719.x, 2933033, 20573181.
34. Bissel SJ, Wang G, Bonneh-Barkay D, Starkey A, Trichel AM, Murphey-Corb M, Wiley CA. Systemic and brain macrophage infections in relation to the development of simian immunodeficiency virus encephalitis. J Virol 2008, 82:5031-5042. 10.1128/JVI.02069-07, 2346725, 18337567.
35. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486. 10.1212/WNL.41.4.479, 2011243.
36. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645. 10.1093/brain/awn016, 2408940, 18339640.
37. Venneti S, Wiley CA, Kofler J. Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol 2009, 4:227-243. 10.1007/s11481-008-9142-2, 2682630, 19052878.
38. Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, Barkhof F, Jonker C, Kloet RW, Lammertsma AA, et al. Microglial activation in healthy aging. Neurobiol Aging 2012, 33:1067-1072. 10.1016/j.neurobiolaging.2010.09.016, 21051106.
39. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 2001, 101:249-255.
40. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483. 10.1146/annurev.immunol.021908.132532, 19105661.
41. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006, 116:193-201. 1307561, 16341263.
42. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, Ershler WB, Dai J, Fraser P, Hyslop PS, et al. Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004, 18:44-46. 10.1097/00002093-200401000-00009, 15195463.
43. Rosen RF, Walker LC, Levine H. PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging 2011, 32:223-234. 10.1016/j.neurobiolaging.2009.02.011, 2891164, 19329226.
44. Cork LC, Masters C, Beyreuther K, Price DL. Development of senile plaques. Relationships of neuronal abnormalities and amyloid deposits. Am J Pathol 1990, 137:1383-1392. 1877724, 1701963.
45. Gearing M, Tigges J, Mori H, Mirra SS. A beta40 is a major form of beta-amyloid in nonhuman primates. Neurobiol Aging 1996, 17:903-908. 10.1016/S0197-4580(96)00164-9, 9363802.
46. Kimura N, Tanemura K, Nakamura S, Takashima A, Ono F, Sakakibara I, Ishii Y, Kyuwa S, Yoshikawa Y. Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. Biochem Biophys Res Commun 2003, 310:303-311. 10.1016/j.bbrc.2003.09.012, 14521910.
47. Kodama R, Yang X, Saski Y, Iwashige S, Tanigawa Y, Yoshikawa T, Nagaoka T, Kamimura Y, Maeda H. Age-related lesions in the cerebrum in middle-aged female cynomolgus monkeys. Toxicol Pathol 2010, 38:303-311. 10.1177/0192623309358904, 20124492.
48. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133:1328-1341. 10.1093/brain/awq065, 2859152, 20403962.
49. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113. 10.1016/j.bbr.2008.02.016, 2601528, 18359102.
50. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842. 10.1038/nm1782, 2772133, 18568035.
51. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:352-358. 10.1016/j.nbd.2009.05.024, 2725199, 19523517.
52. van Helmond Z, Miners JS, Kehoe PG, Love S. Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 2010, 20:468-480. 10.1111/j.1750-3639.2009.00321.x, 19725829.
53. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357. 10.1038/nature04533, 16541076.
54. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006, 572:477-492. 10.1113/jphysiol.2005.103754, 1779683, 16469784.
55. Van Helmond Z, Boche D, Nicoll J, Holmes C, Neal J, Love S. Oligomeric Aβ levels following Aβ42 immunization. Neuropathol Appl Neurobiol 2009, 35:25.
56. Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Masliah E, Nicoll JA, Sabbagh MN, Beach TG, et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 2010, 5:39. 10.1186/1750-1326-5-39, 2959013, 20929585.
57. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, Nolte MW, Perez-Cruz C, van der Auwera I, van Leuven F, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010, 30:10369-10379. 10.1523/JNEUROSCI.5721-09.2010, 20685980.
58. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11:556-561. 10.1038/nm1234, 15834427.
59. Chauhan NB. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 2007, 85:451-463. 10.1002/jnr.21110, 17086547.
60. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008, 28:4231-4237. 10.1523/JNEUROSCI.5161-07.2008, 2685151, 18417702.
61. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001, 7:369-372. 10.1038/85525, 11231639.
62. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919. 10.1038/78682, 10932230.
63. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003, 23:8532-8538.
64. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 2005, 64:743-753. 10.1097/01.jnen.0000178444.33972.e0, 16141783.
65. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004, 15:11-20. 10.1016/j.nbd.2003.09.015, 14751766.
66. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006, 65:1040-1048. 10.1097/01.jnen.0000240466.10758.ce, 17086100.
67. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131. 10.1212/01.WNL.0000148590.39911.DF, 15642916.
68. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 2006, 63:538-543. 10.1001/archneur.63.4.538, 16606766.
69. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009, 19:392-398. 10.1111/j.1750-3639.2008.00188.x, 18637012.
70. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998, 153:31-37. 10.1016/S0002-9440(10)65542-3, 1852933, 9665462.
71. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604. 10.1016/j.immuni.2010.05.007, 20510870.
72. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
73. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969. 10.1038/nri2448, 2724991, 19029990.
74. Kofler J, Bissel SJ, Stauffer M, Starkey A, Wiley CA. Classical and Alternative Activation States of Human Adult Microglia. J Neuropathol Exp Neurol 2010, 69:525-526.
75. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP + PS1 transgenic mice. Neurobiol Aging 2001, 22:1007-1012. 10.1016/S0197-4580(01)00292-5, 11755009.
76. Hickman SE, Allison EK. El Khoury J: Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008, 28:8354-8360. 10.1523/JNEUROSCI.0616-08.2008, 2597474, 18701698.
77. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005, 25:8240-8249. 10.1523/JNEUROSCI.1808-05.2005, 16148231.
78. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol 2008, 181:6503-6513.
79. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 2010, 184:5333-5343. 10.4049/jimmunol.0903382, 20368278.
80. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 46:1078-1084. 10.1086/529197, 18444828.
81. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9:1-17.
82. Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 2010, 53:303-321. 10.1007/978-90-481-9078-2_14, 20593273.
83. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002, 169:4697-4701.
84. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007, 4:9. 10.1186/1742-4933-4-9, 2235886, 18072962.
85. Garcia-Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM, Behre U, Iturbe EB, Catteau G, Thomas F, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010, 46:142-151. 10.1016/j.jadohealth.2009.11.205, 20113920.
86. Shahidi S, Ghareghani NN, Mortazavi M, Sadeghi S, Adeli R. The evaluation of Tetanus-diphtheria (Td) vaccine impacts on immune response to hepatitis B (HB) vaccine in non-responder dialysis patients. J Res Med Sci 2011, 16:598-604. 3214370, 22091281.
87. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gomez-Campdera JA, Navarro ML, Merino JM, Martin-Ancel A, Roca J, Garcia-Del-Ri M, et al. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr Infect Dis J 2007, 26:1-7. 10.1097/01.inf.0000247070.60063.09, 17195697.